{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:15:45Z","timestamp":1778868945912,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union and State Saxony-Anhalt","award":["Thera4Age project (grant ZS\/2023\/12\/182764)"],"award-info":[{"award-number":["Thera4Age project (grant ZS\/2023\/12\/182764)"]}]},{"name":"State Saxony-Anhalt","award":["Scholarship"],"award-info":[{"award-number":["Scholarship"]}]},{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Toll-like receptor 7 (TLR7) recognizes single-stranded RNA and plays a crucial role in initiating immune responses against viral pathogens. This study characterizes SZU-106, a recently developed Toll-like receptor 7 (TLR7) agonist, focusing on its physicochemical and biological properties as key determinants for assessing its suitability for drug product development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Distribution coefficients (LogD) of SZU-106 were determined in silico and confirmed experimentally by the shake-flask method. Stress stability tests were performed by incubation at different pH conditions using temperatures between room temperature and 60\u00b0C. HPLC ESI\u2013MS\/MS analysis was applied to determine the main degradation products. Cytotoxicity tests with different reporter cell lines allowed excluding TRL7-mediated as well as unspecific cytotoxicity in THP-1 monocytes and macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis of distribution coefficients conducted at pH 5.6 and 7.4 confirmed the predominantly hydrophilic nature of SZU-106. Stress stability testing revealed the stability of SZU-106 in neutral aqueous solutions, while rapid degradation was noted under acidic and basic conditions with rate constants of 2.21\u00b710\u20133 d-1 to 0.39\u00a0h-1. HPLC ESI\u2013MS\/MS analysis showed that SZU-106 primarily degrades via hydrolytic cleavage of its amide bonds, with four major degradation products identified and structurally characterized. Cytotoxicity assays with THP-1 monocytes and differentiated macrophages at increasing drug concentrations (10 -1000\u00a0\u00b5M) illustrated no off-target cytotoxicity and only mild, time-dependent, receptor-mediated effects in TLR7-overexpressing THP-1 cells at high SZU-106 concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This evaluation of SZU-106 supports its further development as a therapeutic TLR7 agonist, with formulation strategies representing the next stage for drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04031-5","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:44:10Z","timestamp":1772066650000},"page":"1177-1188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physicochemical and Biological Characterization of the TLR7 Agonist SZU-106"],"prefix":"10.1007","volume":"43","author":[{"given":"Martin","family":"Herbst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Kipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-9033","authenticated-orcid":false,"given":"Christian","family":"Wischke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"4031_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/164_2021_543","volume":"276","author":"V Kumar","year":"2022","unstructured":"Kumar V. Toll-like receptors in adaptive immunity. Handb Exp Pharmacol. 2022;276:95\u2013131. https:\/\/doi.org\/10.1007\/164_2021_543.","journal-title":"Handb Exp Pharmacol"},{"key":"4031_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","volume":"33","author":"SW Brubaker","year":"2015","unstructured":"Brubaker SW, Bonham KS, Zanoni I, et al. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33:257\u201390. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112240.","journal-title":"Annu Rev Immunol"},{"key":"4031_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010663","volume":"25","author":"YS Liu","year":"2024","unstructured":"Liu YS, Wang JX, Jin GY, et al. Combination therapy with a TLR7 agonist and a BRD4 inhibitor suppresses tumor growth via enhanced immunomodulation. Int J Mol Sci. 2024;25: 663. https:\/\/doi.org\/10.3390\/ijms25010663.","journal-title":"Int J Mol Sci"},{"key":"4031_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","volume":"9","author":"EJ Hennessy","year":"2010","unstructured":"Hennessy EJ, Parker AE, O\u2019Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293\u2013307. https:\/\/doi.org\/10.1038\/nrd3203.","journal-title":"Nat Rev Drug Discov"},{"key":"4031_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102172","volume":"70","author":"A Kaur","year":"2022","unstructured":"Kaur A, Baldwin J, Brar D, et al. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr Opin Chem Biol. 2022;70: 102172. https:\/\/doi.org\/10.1016\/j.cbpa.2022.102172.","journal-title":"Curr Opin Chem Biol"},{"key":"4031_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112238","volume":"193","author":"C Patinote","year":"2020","unstructured":"Patinote C, Karroum NB, Moarbess G, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes. Eur J Med Chem. 2020;193: 112238. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112238.","journal-title":"Eur J Med Chem"},{"key":"4031_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","volume":"13","author":"T Kawai","year":"2006","unstructured":"Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13:816\u201325. https:\/\/doi.org\/10.1038\/sj.cdd.4401850.","journal-title":"Cell Death Differ"},{"key":"4031_CR8","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1002\/iid3.839","volume":"11","author":"YT Dabi","year":"2023","unstructured":"Dabi YT, Ajagbe AO, Degechisa ST. Toll-like receptors in pathogenesis of neurodegenerative diseases and their therapeutic potential. Immunity Inflamm Dis. 2023;11:e839. https:\/\/doi.org\/10.1002\/iid3.839.","journal-title":"Immunity Inflamm Dis"},{"key":"4031_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121302","volume":"280","author":"B Singh","year":"2022","unstructured":"Singh B, Maharjan S, Pan DC, et al. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer. Biomaterials. 2022;280: 121302. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121302.","journal-title":"Biomaterials"},{"key":"4031_CR10","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation Resiquimod for the treatment of cutaneous T-cell lymphoma. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu3161653-public-summary-opinion-orphan-designation-resiquimod-treatment-cutaneous-t-cell-lymphoma_en.pdf. Accessed 15 Dez 2024."},{"key":"4031_CR11","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00620-x","volume":"23","author":"D Varshney","year":"2021","unstructured":"Varshney D, Qiu SY, Graf TP, et al. Employing drug delivery strategies to overcome challenges using TLR7\/8 agonists for cancer immunotherapy. AAPS J. 2021;23: 90. https:\/\/doi.org\/10.1208\/s12248-021-00620-x.","journal-title":"AAPS J"},{"key":"4031_CR12","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1021\/acsomega.9b02138","volume":"4","author":"JT Evans","year":"2019","unstructured":"Evans JT, Bess LS, Mwakwari SC, et al. Synthetic toll-like receptors 7 and 8 agonists: structure-activity relationship in the oxoadenine series. ACS Omega. 2019;4:15665\u201377. https:\/\/doi.org\/10.1021\/acsomega.9b02138.","journal-title":"ACS Omega"},{"key":"4031_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1039\/d1md00031d","volume":"12","author":"D Kaushik","year":"2021","unstructured":"Kaushik D, Kaur A, Petrovsky N, et al. Structural evolution of toll-like receptor 7\/8 agonists from imidazoquinolines to imidazoles. RSC Med Chem. 2021;12:1065\u2013120. https:\/\/doi.org\/10.1039\/d1md00031d.","journal-title":"RSC Med Chem"},{"key":"4031_CR14","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1021\/jm0203581","volume":"45","author":"KK Hirota","year":"2002","unstructured":"Hirota KK, Niimoto K, Kumihara H, Sajiki H, Isobe Y, Takaku H, Tobe M, Ogita H, Ogino T, Ichii S, Kurimoto A, Kawakami H. Discovery of 8-hydroxyadenines as a novel type of interferon inducer. J Med Chem. 2002;45:5419\u201322. https:\/\/doi.org\/10.1021\/jm0203581.","journal-title":"J Med Chem"},{"key":"4031_CR15","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.7150\/ijms.49983","volume":"17","author":"G Zhong","year":"2020","unstructured":"Zhong G, Jin G, Zeng W, et al. Conjugation of TLR7 agonist combined with demethylation treatment improves whole-cell tumor vaccine potency in acute myeloid leukemia. Int J Med Sci. 2020;17:2346\u201356. https:\/\/doi.org\/10.7150\/ijms.49983.","journal-title":"Int J Med Sci"},{"key":"4031_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cells11131986","volume":"11","author":"H Chi","year":"2022","unstructured":"Chi H, Hao Y, Wang X, et al. A therapeutic whole-tumor-cell vaccine covalently conjugated with a TLR7 agonist. Cells. 2022;11: 1986. https:\/\/doi.org\/10.3390\/cells11131986.","journal-title":"Cells"},{"key":"4031_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11882-011-0233-4","volume":"12","author":"D Matesic","year":"2012","unstructured":"Matesic D, Lenert A, Lenert P. Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity. Curr Allergy Asthma Rep. 2012;12:8\u201317. https:\/\/doi.org\/10.1007\/s11882-011-0233-4.","journal-title":"Curr Allergy Asthma Rep"},{"key":"4031_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-53","volume":"13","author":"L Greiff","year":"2012","unstructured":"Greiff L, Cervin A, Ahlstrom-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012;13: 53. https:\/\/doi.org\/10.1186\/1465-9921-13-53.","journal-title":"Respir Res"},{"key":"4031_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105750","volume":"122","author":"MH Hu","year":"2022","unstructured":"Hu MH, Lin JH, Huang Q. Discovery of a fluorescent, long chain-bridged bispurine that selectively targets the c-MYC G-quadruplex. Bioorg Chem. 2022;122: 105750. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105750.","journal-title":"Bioorg Chem"},{"key":"4031_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejps.2015.05.008","volume":"76","author":"A Andres","year":"2015","unstructured":"Andres A, Roses M, Rafols C, et al. Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts. Eur J Pharm Sci. 2015;76:181\u201391. https:\/\/doi.org\/10.1016\/j.ejps.2015.05.008.","journal-title":"Eur J Pharm Sci"},{"key":"4031_CR21","doi-asserted-by":"publisher","unstructured":"Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. 2018;2018:https:\/\/doi.org\/10.1101\/pdb.prot095497","DOI":"10.1101\/pdb.prot095497"},{"key":"4031_CR22","doi-asserted-by":"publisher","first-page":"113959","DOI":"10.1016\/j.bcp.2020.113959","volume":"177","author":"H Muley","year":"2020","unstructured":"Muley H, Fado R, Rodriguez-Rodriguez R, et al. Drug uptake-based chemoresistance in breast cancer treatment. Biochem Pharmacol. 2020;177:113959. https:\/\/doi.org\/10.1016\/j.bcp.2020.113959.","journal-title":"Biochem Pharmacol"},{"key":"4031_CR23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","volume":"59","author":"LM Bareford","year":"2007","unstructured":"Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliver Rev. 2007;59:748\u201358. https:\/\/doi.org\/10.1016\/j.addr.2007.06.008.","journal-title":"Adv Drug Deliver Rev"},{"key":"4031_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrd3187","volume":"9","author":"K Sugano","year":"2010","unstructured":"Sugano K, Kansy M, Artursson P, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nature Reviews Drug Discovery. 2010;9:597\u2013614. https:\/\/doi.org\/10.1038\/nrd3187.","journal-title":"Nature Reviews Drug Discovery"},{"key":"4031_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-physiol-021119-034627","volume":"82","author":"E Boedtkjer","year":"2020","unstructured":"Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103\u201326. https:\/\/doi.org\/10.1146\/annurev-physiol-021119-034627.","journal-title":"Annu Rev Physiol"},{"key":"4031_CR26","doi-asserted-by":"publisher","unstructured":"Erra D\u00edaz F, Dantas E, Geffner J. Unravelling the Interplay between Extracellular Acidosis and Immune Cells. Mediators Inflamm. 2018;2018(1):1218297. https:\/\/doi.org\/10.1155\/2018\/1218297.","DOI":"10.1155\/2018\/1218297"},{"key":"4031_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/PL00012496","volume":"59","author":"A Avdeef","year":"2002","unstructured":"Avdeef A, Testa B. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. CMLS Cellular and Molecular Life Sciences. 2002;59:1681\u20139. https:\/\/doi.org\/10.1007\/PL00012496.","journal-title":"CMLS Cellular and Molecular Life Sciences"},{"key":"4031_CR28","doi-asserted-by":"publisher","unstructured":"OECD. Test No. 107: Partition Coefficient (n-octanol\/water): Shake Flask Method. OECD Guidelines for the Testing of Chemicals, OECD Publishing, Paris, 1995, pp. 1. https:\/\/doi.org\/10.1787\/9789264069626-en.","DOI":"10.1787\/9789264069626-en"},{"key":"4031_CR29","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1021\/acsmedchemlett.3c00290","volume":"14","author":"CJ Patterson-Gardner","year":"2023","unstructured":"Patterson-Gardner CJ, Pavelich GM, Cannon AT, et al. Adaptation of empirical methods to predict the LogD of triazine macrocycles. ACS Med Chem Lett. 2023;14:1378\u201382. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00290.","journal-title":"ACS Med Chem Lett"},{"key":"4031_CR30","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","volume":"28","author":"X Liu","year":"2010","unstructured":"Liu X, Testa B, Fahr A. Lipophilicity and its relationship with passive drug permeation. Pharmaceutical Research. 2010;28:962\u201377. https:\/\/doi.org\/10.1007\/s11095-010-0303-7.","journal-title":"Pharmaceutical Research"},{"key":"4031_CR31","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260\u201387. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01724.x.","journal-title":"Br J Pharmacol"},{"key":"4031_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy M, Patel RD, Prajapati PN, et al. Development of forced degradation and stability indicating studies of drugs-a review. J Pharm Anal. 2014;4:159\u201365. https:\/\/doi.org\/10.1016\/j.jpha.2013.09.003.","journal-title":"J Pharm Anal"},{"key":"4031_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0121-9","volume":"8","author":"J Zhu","year":"2015","unstructured":"Zhu J, He S, Du J, et al. Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma. J Hematol Oncol. 2015;8: 21. https:\/\/doi.org\/10.1186\/s13045-015-0121-9.","journal-title":"J Hematol Oncol"},{"key":"4031_CR34","unstructured":"Jin G, Wang Z, Tang L. Novel small molecule immune agonists and immune targeting compounds and applications thereof. WO 2019\/192454 A1; 2019."},{"key":"4031_CR35","unstructured":"International Council for Harmonisation (ICH). ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures Q2 (R2). ICH Guidelines; 30 November 2023. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2%28R2%29_Guideline_2023_1130.pdf. Accessed 14 Feb 2025."},{"key":"4031_CR36","unstructured":"European Medicines Agency, ICH Topic Q1A (R2) Stability Testing of New Drug Substances and Products. (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf. Accessed 14. Feb 2025."},{"key":"4031_CR37","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1002\/ejoc.200400316","volume":"2004","author":"D Zahn","year":"2004","unstructured":"Zahn D. On the role of water in amide hydrolysis. Eur J Org Chem. 2004;2004:4020\u20133. https:\/\/doi.org\/10.1002\/ejoc.200400316.","journal-title":"Eur J Org Chem"},{"key":"4031_CR38","doi-asserted-by":"publisher","unstructured":"Packer J, Thomson AL, Vaughan J. The Base-cutulysed Hydrolysis of Certain Aliphatic Amides and p-Alkylbenzumides. J Chem Soc. 1955;2601\u20132603. https:\/\/doi.org\/10.1039\/JR9550002601.","DOI":"10.1039\/JR9550002601"},{"key":"4031_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jhazmat.2009.10.053","volume":"175","author":"K Mahalik","year":"2010","unstructured":"Mahalik K, Sahu JN, Patwardhan AV, et al. Kinetic studies on hydrolysis of urea in a semi-batch reactor at atmospheric pressure for safe use of ammonia in a power plant for flue gas conditioning. J Hazard Mater. 2010;175:629\u201337. https:\/\/doi.org\/10.1016\/j.jhazmat.2009.10.053.","journal-title":"J Hazard Mater"},{"key":"4031_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","volume":"23","author":"W Chanput","year":"2014","unstructured":"Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23:37\u201345. https:\/\/doi.org\/10.1016\/j.intimp.2014.08.002.","journal-title":"Int Immunopharmacol"},{"key":"4031_CR41","doi-asserted-by":"publisher","unstructured":"Scheurlen KM, Snook DL, Gardner SA, et al. Macrophage differentiation and polarization into an M2-like phenotype using a human monocyte-like THP-1 leukemia cell line. J Vis Exp. 2021;e62652. https:\/\/doi.org\/10.3791\/62652.","DOI":"10.3791\/62652"},{"key":"4031_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008668","volume":"5","author":"M Daigneault","year":"2010","unstructured":"Daigneault M, Preston JA, Marriott HM, et al. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE. 2010;5: e8668. https:\/\/doi.org\/10.1371\/journal.pone.0008668.","journal-title":"PLoS ONE"},{"key":"4031_CR43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28:1248\u201350. https:\/\/doi.org\/10.1038\/nbt1210-1248.","journal-title":"Nat Biotechnol"},{"key":"4031_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10495-016-1333-3","volume":"22","author":"G Banfalvi","year":"2017","unstructured":"Banfalvi G. Methods to detect apoptotic cell death. Apoptosis. 2017;22:306\u201323. https:\/\/doi.org\/10.1007\/s10495-016-1333-3.","journal-title":"Apoptosis"},{"key":"4031_CR45","doi-asserted-by":"publisher","unstructured":"Rieger AM, Hall BE, Schang LM, et al. Conventional apoptosis assays using propidium iodide generate a significant number of false positives that prevent accurate assessment of cell death. J Immunol Methods. 2010;358:81\u201392. https:\/\/doi.org\/10.1016\/j.jim.2010.03.019.","DOI":"10.1016\/j.jim.2010.03.019"},{"key":"4031_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/Bf00269095","volume":"100","author":"M Vitale","year":"1993","unstructured":"Vitale M, Zamai L, Mazzotti G, et al. Differential kinetics of propidium iodide uptake in apoptotic and necrotic thymocytes. Histochemistry. 1993;100:223\u20139. https:\/\/doi.org\/10.1007\/Bf00269095.","journal-title":"Histochemistry"},{"key":"4031_CR47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/17460441.3.6.655","volume":"3","author":"AL Niles","year":"2008","unstructured":"Niles AL, Moravec RA, Riss TL. Update on in vitro cytotoxicity assays for drug development. Expert Opin Drug Discov. 2008;3:655\u201369. https:\/\/doi.org\/10.1517\/17460441.3.6.655.","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"4031_CR48","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mco2.108","volume":"2021","author":"X Liu","year":"2020","unstructured":"Liu X, Xie X, Ren Y, et al. The role of necroptosis in disease and treatment. MedComm. 2020;2021(2):730\u201355. https:\/\/doi.org\/10.1002\/mco2.108.","journal-title":"MedComm"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04031-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04031-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04031-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:20Z","timestamp":1778867660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04031-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4031"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04031-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}